Preferred Label : lifitegrast;
MeSH note : an LFA-1 antagonist;
CISMeF synonym : SAR 1118;
MeSH synonym : (2S)-2-(((2-(benzofuran-6-ylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6-
yl)carbonyl)amino)-3-(3-(methylsulfonyl)phenyl)propanoic acid; L-phenylalanine, n-((2-(6-benzofuranylcarbonyl)-5,7-dichloro-1,2,3,4-tetrahydro-6-isoquinolinyl)carbonyl)-3-(methylsulfonyl)-;
MeSH hyponym : SHP606; SAR-1118;
Is substance : O;
UNII : 038E5L962W;
Origin ID : C575157;
UMLS CUI : C3713860;
- ATC code(s)
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Manual BTNT mappings - CISMeF
- MeSH indexing information
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00383
2018
false
false
false
Canada
French
English
drug information
lifitegrast
drug evaluation
drug approval
canada
lymphocyte Function-Associated Antigen-1
dry eye syndromes
adult
aged
administration, ophthalmic
ophthalmic solutions
treatment outcome
risk assessment
lifitegrast
product surveillance, postmarketing
lifitegrast
sulfones
phenylalanine
sulfones
phenylalanine
phenylalanine
sulfones
phenylalanine
---